Reapplix has established that one of the keys to successful wound treatment lies in the body’s capacity to heal – and each patient is central to that process. Founded in 2008, Reapplix specializes in the biological treatment and management of diabetic foot ulcers. The patented 3CPatch® System is an innovative, evidence-based biological wound therapy made entirely from the patient’s own blood – nothing else. Headquartered in Denmark, with sales and distribution teams in the US and Europe, Reapplix won the 2018 EY Entrepreneur of the Year Award in the life science category. Every wound is personal.